Our Mission: Better Medicines, Faster
Gimerny AI was founded in 2021 with a singular conviction: the drug discovery timeline, averaging 12-15 years and $2.6 billion per approved drug, is an engineering problem that AI can solve. We build computational platforms that compress this timeline from decades to months, making it possible to explore chemical space systematically rather than searching it by trial and error.
Our team combines deep expertise in machine learning, computational chemistry, medicinal chemistry, and clinical development. We are scientists building tools for scientists, and every product we ship is validated against the standard that matters: does it produce better drug candidates, faster?
Scientific Advisory Board
Leading researchers and industry veterans guiding our scientific direction.
Prof. Michael Thompson
Chair of Computational Biology
Stanford University
Professor Thompson's lab pioneered the application of deep learning to protein-ligand binding affinity prediction. He is a member of the National Academy of Sciences and has published over 240 papers in computational biology and machine learning.
Prof. Yuki Tanaka
Director, Center for Molecular Simulation
University of Tokyo
Professor Tanaka is a world-leading expert in molecular dynamics simulation and enhanced sampling methods. Her work on coarse-grained models for drug-membrane interactions has transformed how the industry approaches ADMET prediction.
Prof. Anna Kowalski
Professor of Machine Learning for Drug Design
ETH Zurich
Professor Kowalski leads the ML4Drug lab at ETH Zurich, focusing on generative models for molecular design. She is the creator of the widely-used MolScore benchmark and serves on the editorial board of the Journal of Chemical Information and Modeling.
Dr. James Okonkwo
Former SVP of Research & Development
Pfizer Inc.
Dr. Okonkwo spent 22 years at Pfizer, where he oversaw the computational chemistry division and championed the integration of AI into the drug discovery pipeline. He led the team that identified three blockbuster drug candidates using computational methods.
Our Journey
Gimerny AI founded in Berlin by Dr. Elena Richter and Dr. Marcus Chen
Accepted into Y Combinator (W21 batch)
GimernyDiscover alpha launch, first pharma partnership
$8M Seed round led by Lux Capital
GimernyGenome platform launch, 15 enterprise customers
$25M Series A led by a16z Bio
NVIDIA Inception program, opened San Francisco office
AWS Startup program, SOC 2 Type II certification
GimernyMolecule launch, 500K molecules generated
First IND-enabling candidate from platform, ISO 27001 certified
London and Singapore offices opened, 100+ employees
GimernySynth launch, partnership with top-5 pharma company
$42.5M Series B led by Sequoia Capital
GimernyTrial launch, HIPAA certification
2M+ molecules generated, 45+ enterprise customers
Named in Forbes AI 50, 3 pipeline candidates in preclinical
Global Offices
Berlin, Germany
Global Headquarters
Friedrichstrasse 68, 10117 Berlin, Germany
+49 30 2589 4100
berlin@gimerny.com
San Francisco, United States
US Headquarters
535 Mission Street, Suite 1800, San Francisco, CA 94105
+1 (415) 580-7200
sf@gimerny.com
London, United Kingdom
EMEA Office
71 Queen Victoria Street, London EC4V 4AY, United Kingdom
+44 20 7946 0958
london@gimerny.com
Singapore, Singapore
APAC Office
1 Raffles Place, #20-61, Tower 2, Singapore 048616
+65 6808 7300
singapore@gimerny.com
Backed by Leading Investors
Total funding: $78M